EpicentRx is currently in the thick of discussions at JP Morgan with cardiovascular (CV) companies that have expressed interest in RRx-001 (nibrozetone) as a licensable CV agent. Here is a sample of its curriculum vitae or CV in CV (or adjacent to CV) with links:
- Pulmonary hypertension and heart failure American Heart Association (AHA) Abstract
- Myocardial infarction American Physiological Society Abstract
- Hypercholesterolemia and hyperlipidemia Journal of Clinical Lipidology Abstract
- Cardioprotection from doxorubicin-induced cardiotoxicity published peer-reviewed manuscript
- Hemorrhagic shock and ischemia-reperfusion injury published peer-reviewed manuscript
- Hypoxic nitric oxide donation published peer-reviewed manuscript
- Nrf2 induction published peer-reviewed manuscript
- NLRP3 inhibition published peer-reviewed manuscript
References are available on request.